Aclarion, Inc.
ACONAbout the company
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine.
Investment snapshot
Positive
1
BUY / PASS
Neutral / negative
2 / 13
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 13 investors flag at least one valuation criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | Not ranked | PASS | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-18 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-18 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-18 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-18 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-18 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-18 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-18 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-03-18 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-18 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-18 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-05 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-11-05 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✓ 8✗ 20▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio0.1x✓Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise ValueN/A (EV <= 0)✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per Share0.1x✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-527.3%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-159.8%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=0.1x✓MarksP/E < 15 or P/B < 2.0Discount to Intrinsic Value✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low100% of trailing low ($1.56)✓Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-224.89%; #5702/6340 (top 89.9%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+3.2927; #433/6449 (top 6.7%)✓AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share0.12x✓SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.0219; #4743/5247 (top 90.4%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-159.81%; #4169/4519 (top 92.3%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-52.44%; #5218/6202 (top 84.1%)✗OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy$-7.0M✗BuffettPositive and growingFCF Positive and Growing$-7.2M✗LynchPositive and growingOperating Cash Flow$-7.2M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-52.40%, ROA=-52.91%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-159.8%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/3 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-539.1%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency0/5 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-7.2M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-159.81%; #4169/4519 (top 92.3%)✗OshaughnessyTop 10% of eligible cross-section - Growth0% pass✓ 2✗ 11▾
No clean pass — all 8 investors flag at least one growth criterion
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthN/A (no inventory)✓LynchInventory growth < Revenue growthEPS Growth Direction✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency0/5 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth24.8%✓Ackman>= 5%Positive EPS Growth Frequency✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin -0.4% -> 9.0%, operating margin -6466.5% -> -9312.5%✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR✗SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Profitability6% pass✓ 4✗ 31▾
15 of 16 flag ACON's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)0/6 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)0/6 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-364.9%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-9312.5% (latest)✗BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-7.0M✗BuffettPositive and growingEarnings Variance (10-yr CoV)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-68.3%✗Lynch> 15%EBIT / Enterprise ValueN/A (EV <= 0)✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-52.91%✗PiotroskiROA > 0ROA Change YoY-329.31% -> -52.91% (delta: +276.41%)✓PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-52.40%, ROA=-52.91%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY-85.2% -> 9.0%✓PiotroskiImproved YoYPre-Tax Income / Revenue-10260.0%✗Dreman>= 8%Net Income / Shareholders' Equity-68.3%✗Dreman> 12%Margin of SafetyP/B=0.1x✓PabraiP/B < 1.5 or P/E < 15Return on Equity-364.9% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic Value✗Marks>= 20% below intrinsic valuePositive Net Income Frequency0/5 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-10789.2%✗Ackman>= 15%Net Income / Shareholders Equity-68.3%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-6466.5% (2023) -> -9312.5% (2025)✗TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin -0.4% -> 9.0%, operating margin -6466.5% -> -9312.5%✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-224.89%; #5702/6340 (top 89.9%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+0.18%; #3437/3702 (top 92.8%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity-68.30%; #4388/5226 (top 84.0%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-1.0116; #5274/5884 (top 89.6%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/5 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Verdicts7% pass✓ 1✗ 13▾
Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS
Overall verdict✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 5)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (1/3)✗AkreFAIL (0/6)✗MarksFAIL (1/5)✗AckmanFAIL (2/9)✗TempletonFAIL (3/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked) - Debt & Leverage8% pass✓ 3✗ 12▾
11 of 12 flag ACON's debt & leverage — Graham, Buffett, Lynch +8 more
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest Coverage✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity✗Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities14.17✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00xDebt Levels✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDA✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity✗Ackman<= 1.0Negative debt-to-equity (higher means less debt)✗AsnessTop 30% of eligible cross-section - Efficiency25% pass✓ 3✗ 8▾
6 of 8 flag ACON's efficiency — Buffett, Greenblatt, Piotroski +3 more
Current Ratio14.17✓Graham>= 2.0ROIC (3-5 yr avg)-627.5%✗Buffett> 10%ROIC - WACC-637.5%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)✗Greenblatt> 25%Current Ratio Change YoY0.71 -> 14.81✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.02x -> 0.01x✗PiotroskiImproved YoYCurrent Assets / Current Liabilities14.17✓Dreman> 1.5Return on Invested Capital✗Munger> 15%ROIC (high and growing)FY2023: ROIC=-206.4%; FY2024: ROIC=-449.0%; FY2025: ROIC=unavailable✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/3 years above 12% (latest -449.0%)✗SleepROIC > 12% in a majority of years
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Share retirement not available for this company.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-09-30 2025-10-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow, depreciation amortization, capex. | Q3 FY 2026 2026-07-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.5Mcurrent | -- | -- | -- | $2.8Mest. | $9.7Kest. | $17.9Best. | $738.4Best. | $271.3Best. |
| Revenue | $98.6K↑46% | $33.7K↑78% | $25.2K↑30% | $21.1K↑11% | $75.7K↑66% | $45.7K↓39% | $75.4K↑25% | $60.4K | $60.3K |
| Operating Income | -$10.6M↓55% | -$2.8M↓50% | -$2.9M↓67% | -$3.0M↓100% | -$7.1M↓28% | -$5.5M↓13% | -$4.9M↑12% | -$5.6M↓88% | -$3.0M |
| Net Income | -$10.1M↓38% | -$2.6M↓54% | -$2.7M↓72% | -$2.9M↓40% | -$7.2M↓3% | -$7.0M↓42% | -$4.9M↑31% | -$7.1M↓43% | -$5.0M |
| EPS (Diluted) | -- | $-0.94↑68% | $-1.12↑59% | $-1.34↑86% | $-13.61↑100% | $-7480.00↓84707% | $-8.82↓573% | $-1.31↑80% | $-6.58 |
| Gross Margin | 29.1%↑471% | 43.9%↑89% | 32.9%↑24% | 17.7%↑175% | 9.0%↑111% | -85.2%↓19717% | -0.4%↑95% | -8.0%↑45% | -14.7% |
| Operating Margin | -10789.2%↓6% | -8164.7%↑16% | -11503.2%↓28% | -14129.3%↓80% | -9312.5%↑23% | -12057.2%↓86% | -6466.5%↑30% | -9201.2%↓88% | -4897.9% |
| ROE | -68.3%↓16% | — | — | — | -56.4%↑92% | -720.9%↓207% | 674.6%↑312% | -317.6%↓923% | 38.6% |
| Total Debt | -- | -- | -- | -- | -- | $0↓100% | $2.6M | $0↓100% | $2.0M |
| Shareholders' Equity | $14.8M↑18% | $14.8M↑18% | $17.0M↑20% | $19.7M↑25% | $12.8M↑1223% | $970.1K↑233% | -$728.0K↓133% | $2.2M↑117% | -$12.8M |
| Current Ratio | 14.17↓17% | 14.17↓17% | 16.20↓32% | 19.65↓9% | 14.81↑1972% | 0.71↑77% | 0.40↓84% | 2.47↑366% | 0.53 |
| Debt / Equity | — | — | — | — | — | 0.00↑100% | -3.56 | 0.00↑100% | -0.16 |
| Operating Cash Flow | -$8.9M↓38% | -$2.0M↓74% | -$2.7M↓42% | -$2.6M↓5% | -$7.2M↓36% | -$5.3M↓45% | -$3.6M↑26% | -$4.9M↓106% | -$2.4M |
| Free Cash Flow | -- | -$2.0M↓73% | -- | -- | -$7.2M↓36% | -$5.3M↓45% | -$3.6M | -- | -- |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Healthcare
ACON vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCA Healthcare, Inc.HCA | $104.2B | $499.05 | $75.6B | $6.8B | -112.6% | -7.71 | 13.0% | 0.97 | 1/9 | 5/9 | 3/7 | 1/3 | F-Score 6 | 4/11 |
| TENET HEALTHCARE CORPTHC | $22.8B | $286.03 | $21.3B | $2.4B | 56.1% | 3.12 | 16.5% | 1.76 | 1/9 | 4/9 | 3/7 | 3/3 | F-Score 6 | 5/11 |
| Guardant Health, Inc.GH | $20.5B | $151.70 | $982.0M | $416.3M | 419.2% | -15.14 | -44.5% | 4.84 | 2/9 | 1/9 | 1/7 | 0/3 | F-Score 5 | 2/11 |
| EXACT SCIENCES CORPEXAS | $20.0B | $104.91 | $3.2B | $207.9M | -8.7% | 0.00 | -6.4% | 2.43 | 2/9 | 1/9 | 3/7 | 0/3 | F-Score 7 | 3/11 |
| Fresenius Medical Care AGFMS | $11.4B | $22.03 | $23.1B | $1.1B | 7.4% | 0.81 | 9.3% | 1.26 | 5/9 | 2/9 | 1/7 | 0/3 | F-Score 8 | 5/11 |
| UNIVERSAL HEALTH SERVICES INCUHS | $11.2B | $194.07 | $17.4B | $1.5B | 20.5% | 0.65 | 11.5% | 1.05 | 4/9 | 6/9 | 5/7 | 1/3 | F-Score 7 | 6/11 |
| DAVITA INC.DVA | $11.0B | $174.56 | $13.6B | $746.8M | -114.7% | -15.78 | 15.0% | 1.29 | 1/9 | 4/9 | 2/7 | 1/3 | F-Score 7 | 3/11 |
| CHEMED CORPCHE | $7.1B | $548.20 | $2.5B | $265.2M | 27.1% | — | 13.4% | 1.05 | 4/9 | 7/9 | 3/7 | 1/3 | F-Score 6 | 6/11 |